


**INFORMATION DISCLOSURE
CITATION**

 Page 2 of 3
 (Use several sheets if necessary)

 Atty. Docket No.
11020-55

 Serial No.
09/763,666

 Applicant
Stephen R. Ash

 Filing Date
February 23, 2001

Group


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial		
<i>SP</i>	4	Olinger GN, Hottenrott C, Mulder DG, Maloney JV, Miller J, Patterson RW, Sullivan SF, Buckberg GD. Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> 72: 503-511, October 1976.
<i>SP</i>	6	Dzik WH, Kirkley SP. Citrate toxicity during massive blood transfusion. <i>Transfusion Medicine Reviews</i> 2:76-94, June 1988.
<i>SP</i>	1	Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. <i>Am J Kidney Dis</i> 9: 235-236, March 1987.
<i>SP</i>	0	Lohr JW, Slusher S, Diederich D. Safety of regional citrate hemodialysis in acute renal failure. <i>Am J Kidney Dis</i> 8:104-107, February 1989.
<i>SP</i>	0	Leray-Moragues H, Bose LY, Canaud B. Gentamicin/sodium citrate mixture: a promising antibiotic lock for preventing catheter related infections. Lapeyronie University Hospital, Montpellier, France.
<i>SP</i>	6	Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. <i>Am J Kidney Dis</i> 8:196-201, September 1986.
<i>SP</i>	1	Purchase L, Gault MH. Hemodialysis with a Permcath kept open with streptokinase and later citrate in a heparin-sensitive patient. <i>Nephron</i> 48:119-120, 1991.
<i>SP</i>	0	Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. <i>Am J Kidney Dis</i> 27:519-524, April 1996.
<i>SP</i>	8	Sodemann K, Lubrich-Birkner I, Berger O, Baumert J, Feldmer B, Von Hodenberg E. Gentamicin/sodium-citrate mixture as antibiotic-lock technique for salvage and prevention of catheter-related infections - A four year trial. <i>J Am Soc Nephrol</i> 8:173A, 1997.
Examiner		
Date Considered	5/28/03	

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 RECEIVED
 AUG 21 2001
 TECHNOLOGICAL CENTER 3700

**INFORMATION DISCLOSURE
CITATION**

 Page 3 of 3
 (Use several sheets if necessary)

 Atty. Docket No.
11020-55

 Serial No.
09/763,666

 Applicant
Stephen R. Ash

 Filing Date
February 23, 2001

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

 *Examiner
 Initial

P

 Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. *Artif Organs* 22:945-946, 1998.

SP

 Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. *Chest* 103:882-885, March 1993.

RECEIVED

AUG 21 2001

TECHNOLOGY CENTER 3700

Examiner

SAWA

Date Considered

5/28/03

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.